Acumen Pharmaceuticals, Inc.: 10-Q filed 2021-08-16
What Acumen Pharmaceuticals, Inc. reported in its quarterly report filed 2021-08-16 (fiscal Q2 2021): 24 published measures, 62 facts as tagged in accession 0001193125-21-247879.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-08-16
- Fiscal period
- fiscal Q2 2021
- Accession
- 0001193125-21-247879 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acumen Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 72,943,000 | USD | |
| At 2020-12-31 | 44,429,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 4,518,000 | USD | |
| At 2020-12-31 | 6,367,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -106,079,000 | USD | |
| At 2021-03-31 | -45,462,000 | USD | |
| At 2020-12-31 | -18,591,000 | USD | |
| At 2020-06-30 | -15,423,000 | USD | |
| At 2020-03-31 | -13,426,000 | USD | |
| At 2019-12-31 | -11,420,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 68,812,000 | USD | |
| At 2020-12-31 | 43,777,000 | USD | |
| At 2020-06-30 | 3,242,000 | USD | |
| At 2019-12-31 | 6,552,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -61,358,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -88,355,000 | USD | 181 |
| 2020-04-01 to 2020-06-30 | -2,035,000 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -4,080,000 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | -6,634,000 | USD | 181 |
| 2020-01-01 to 2020-06-30 | -3,310,000 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 31,675,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | -6,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -115,320,000 | USD | |
| At 2020-12-31 | -26,965,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 6,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 253,000 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 77,000 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -3,441,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -7,234,000 | USD | 181 |
| 2020-04-01 to 2020-06-30 | -2,035,000 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -4,081,000 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 70,572,000 | USD | |
| At 2020-12-31 | 44,429,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 2,907,000 | USD | |
| At 2020-12-31 | 531,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 3,441,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 7,234,000 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 2,186,000 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 4,458,000 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 2,254,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 4,832,000 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 1,927,000 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 3,977,000 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 556,570 | shares | |
| At 2020-12-31 | 419,124 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 9,241,000 | USD | |
| At 2020-12-31 | 8,374,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,000 | USD | |
| At 2020-12-31 | 0 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 1,651,000 | USD | |
| At 2020-12-31 | 543,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 1,187,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 2,402,000 | USD | 181 |
| 2020-04-01 to 2020-06-30 | 259,000 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 481,000 | USD | 182 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 19,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 28,000 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -57,917,000 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -81,121,000 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 1,000 | USD | 182 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 741,000 | USD | 181 |
| 2020-01-01 to 2020-06-30 | 380,000 | USD | 182 |
Inspect the source
- Entity
- Acumen Pharmaceuticals, Inc. / CIK 0001576885
- Captured
- SEC response SHA-256
08de987027426e8291dddc89db4572c4046a051c506d88877900df4015644a70
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001576885.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))